Lyme disease vaccine - GlaxoSmithKline/Valneva

Drug Profile

Lyme disease vaccine - GlaxoSmithKline/Valneva

Alternative Names: Borrelia vaccine - GlaxoSmithKline/Valneva; Lyme borreliosis vaccine - GlaxoSmithKline/Valneva; VLA 15

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intercell
  • Developer Valneva
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lyme disease

Most Recent Events

  • 31 Aug 2017 Valneva completes enrolment in its phase-I clinical trial in Lyme disease (Prevention) in Belgium, USA (IM)
  • 24 Jul 2017 Lyme disease vaccine - GlaxoSmithKline/Valneva receives Fast Track designation for Lyme disease [IM,Injection] (Prevention) in USA
  • 23 Feb 2017 Valneva plans a phase II trial for Lyme disease in Q1 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top